WDN:gte 07/13/01 6395-59041 60896.doc

EXPRESS MAIL LABEL NO. EL828141699US
DATE OF DEPOSIT: July 13, 2001
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tripp et al.

Application No.: To be assigned

Filed: Herewith

For: METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY AN INFLAMMATORY RESPONSE MEDIATED BY ENDOGENOUS SUBSTANCE P BY USING ANTI-SUBSTANCE P ANTIBODIES

Examiner: To be assigned

Date: July 13, 2001

Art Unit: To be assigned

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on July 13, 2001 as Express Mail Label No. EL828141699US in an envelope addressed to: BOX PCT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

William D. Noonan

William D. Noonan, M.D.
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(1)

BOX PCT
COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the filing date of a U.S. national stage application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP

By William D. Noonan
William D. Noonan, M.D.
Registration No. 30,878

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391 / Facsimile: (503) 228-9446

WDN:gte 07/13/2001 6395-59041 60892.do

RESS MAIL LABEL NO. EL828141699US
DATE OF DEPOSIT: July 13, 2001
JC18 Rec'd PCT/PTO 13 JUL 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 6395-59041	App: To be assigned
	Applicant: Tripp et al.	
	Filed: Herewith	Art Unit: To be assigned

U.S. PATENT DOCUMENTS

Init.*		Number	Date	Name	Class	Sub	Filed
		4,419,352	Dec. 6, 1983	Cox et al.			
		5,332,817	Jul. 26, 1994	Desai et al.			
		5,340,822	Aug. 23, 1994	Emonds-Alt et al.			
		5,373,003	Dec. 13, 1994	Lowe, III			
		5,410,019	Apr. 25, 1995	Coy et al.			
		5,451,586	Sep. 19, 1995	Lowe, III			
		5,464,820	Nov. 7, 1995	Burton et al.			
		5,484,804	Jan. 16, 1996	Achard et al.			
		5,498,614	Mar. 12, 1996	Desai et al.			
		5,604,241	Feb. 18, 1997	Ito et al.			
		5,620,989	Apr. 15, 1997	Harrison et al.			
		5,688,806	Nov. 18, 1997	Desai et al.			

FOREIGN PATENT DOCUMENTS

		Number	Date	Country	Class	Sub	
		WO 92/16547	1 Oct. 1992	PCT			
		WO 96/29326	26 Sep. 1996	PCT			

OTHER DOCUMENTS

EXAMINER:	DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 6395-59041	App: To be assigned
	Applicant: Tripp et al.	
	Filed: Herewith	Art Unit: To be assigned

			Agro et al., "Inhibition of Murine Intestinal Inflammation by Anti-Substance P Antibody," *Regional Immunology*, 5:120-126, 1993.
			Couraud et al., "Anti-substance P Anti-idiotypic Antibodies," *Journal of Biological Chemistry*, 260(16):9461-9469, 1985.
			Jafarian et al., "Passive Immunization with an Anti-Substance P Antibody Prevents Substance P-and Neurokin A-Induced Bronchospasm in Anesthetized Guinea-Pigs," *Life Sciences*, 57(2):143-153, 1995.
			Maillet et al., "Anti-substance P anti-idiotypic antibodies modulate the secretory process in the rat parotid gland in vitro," *European Journal of Pharmacology*, 187:357-367, 1990.
			Piccioli et al., Neuroantibodies: Ectopic Expression of a Recombinant Anti-Substance P Antibody in the Central Nervous System of Transgenic Mice," *Neuron*, 15:373-384, 1995.
			Swenberg et al., "Development of an anti-idiotypic antibody that blocks substance P primary antibodies and substance P membrane binding," *Brain Research*, 417:131-138, 1987.
			Tripp et al., "Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice," *Journal of Virology*, 74(4):1614-1622, 2000.

EXAMINER:	DATE
*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.	